Last reviewed · How we verify
rHA adjuvant
At a glance
| Generic name | rHA adjuvant |
|---|---|
| Also known as | SE |
| Sponsor | Protein Sciences Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PHASE1, PHASE2)
- RADAR Trial - Randomised Androgen Deprivation and Radiotherapy (PHASE3)
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rHA adjuvant CI brief — competitive landscape report
- rHA adjuvant updates RSS · CI watch RSS
- Protein Sciences Corporation portfolio CI